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Pathogenesis of Insulin Resistance
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Abstract
Insulin resistance is interpreted as being a normal or raised insulin level giving rise to a
biological reactionwhich is attenuated in effect; classically this cites to theweakened
sensitivity to the disposal of insulin arbitrate glucose.Compensatory hyperinsulinemia
eventuates when the secretion of the β cells of pancreas gets elevated to sustain the level
of blood glucose in normal levels. The term insulin resistance syndrome is used to refer to a
group of abnormalities and interconnected physical consequences that eventuate in
long-standing insulin-resistant persons. Under standard situations of insulin reactivity,
the response of insulin triggers the intake of glucose into the body cells, for utilization as
energy, and impedes the utilization of fat for energy, as a result of which, the concen-
tration of glucose circulating in the blood decreases. There are a number of risk factors
for insulin resistance. Fourmajormetabolic abnormalities characterize type 2 diabetes
mellitus (T2DM): impaired insulin action, obesity, increased endogenous glucose out-
put, and insulin secretory dysfunction. The evolution (and subsequent progression) of
type 2 diabetesmellitus is delineatedby a gradual deterioration of glucose tolerance over
several years. Glucose tolerance testing, hyperinsulinemic euglycemic clamp,modified
insulin suppression test, homeostaticmodel assessment (HOMA), and quantitative
insulin sensitivity check index (QUICKI)method for insulin assessment are someof the
methods bywhich insulin resistance can bemeasured.Moreover, longer-term effective
researches as well are essential to preferably ascertain the significance of the glycemic
index in the blood glucose regulation and to prevent the complications of diabetes,
particularly in relations to insulin resistance risk factors. The possible role of insulin
resistance in the glycemic index in depleting oxidative stress postprandially and related
pro-inflammatory situations alsomerits further appraisal.
Keywords: insulin resistance, compensatory hyperinsulinemia,
type 2 diabetes mellitus, obesity
1. Introduction
One of the most renowned hormones of our body is insulin which enables
glucose to go inside the cells which additionally decreases blood glucose. The hor-
mone insulin is secreted by the pancreas in response to glucose entering the blood-
stream after a meal. Insulin resistance (IR) is contemplated as a pathological
situation in which our body cells decline to react normally to insulin hormone [1].
To avert hyperglycemia and apparent damage to our body organs in the future [2],
insulin production by the body starts when glucose enters into the bloodstream,
predominantly from the dietary carbohydrate digestion and absorption. Under
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standard situations of insulin reactivity, the response of insulin triggers the intake
of glucose into the body cells, for utilization as energy, and impedes the utilization
of fat for energy, as a result of which, the concentration of glucose circulating in the
blood decreases, which results in glucose remaining within the normal range in case
of consumption of a substantial amount of carbohydrates. Carbohydrates contains
sugars, i.e., from only one glucose containing monosaccharides, such as fructose
and glucose; two glucose containing disaccharides, like cane sugar; and many glu-
cose containing polysaccharides (e.g., starches) and glycoprotein, glycolipids, etc.
Fructose, ultimately metabolized into triglycerides inside the liver, stimulates the
production of insulin and is seen to have a more impressive sequel than other
carbohydrates. A customarily increased intake of carbohydrates, and specifically
fructose, imparts to insulin resistance and has been connected to gain of weight and
obesity [3–5]. If surplus blood glucose is not adequately transported into the cells
even in the insulin’s presence, the augmented level of blood glucose can elicit in the
classic hyperglycemic triad of polydipsia (increased thirst), polyphagia (increased
appetite), and polyuria (increased urination). Circumventing carbohydrates, a
zero-carbohydrate diet or conditions of fasting can counteract insulin resistance
[6, 7]. The first narration of insulin resistance is found historically in the 1960s,
soon after the invention of radioimmunoassays helped in making serum insulin
quantification possible and subsequently revealed that people having late-onset
diabetes mellitus had high levels of insulin [8, 9]. Drs. Yalow and Berson [8, 9]
defined insulin resistance as “a state in which a greater than normal amount of
insulin is required to elicit a quantitatively normal response.” The next milestone
discovery in this context was the detection and ascertaining of the insulin receptor
and also the discovery that insulin resistance led to hyperinsulinemia and the fact
that this was interconnected very much with atypical/unconventional binding of
insulin hormone with its receptor in various rodent models [10, 11]. The succeeding
milestone discovery in the history of insulin resistance came with the pioneering
recognition of the receptor for insulin and the observation that high insulin in
blood, secondary to the insulin resistance, was interconnected with atypical binding
of insulin hormone to its receptor [10, 11]. It was not before the year 1976 when the
evidence came that defects in receptor for insulin could be interlinked with resis-
tance to the insulin hormone in humans, provided genetic translational verification
for the significance of insulin resistance [10]. Researchers like Kahn et al. [10]
delineated two syndromes that were distinguished by virilization, acanthosis
nigricans, hirsutism, anovulation, acne, and flawed binding of insulin on the insulin
receptor of lymphocytes circulating in the blood. This initial syndrome was desig-
nated as type A insulin resistance when it took place without the existence of anti-
insulin antibodies and the corresponding accountability of the insulin receptor was
the main factor, and in contrast it was designated as the type B when it occurred
with the clinical characteristics of various autoimmune ailments and it always
occurred when neutralizing anti-insulin antibodies were present [10]. After this
specification of type A and type B syndrome, all rare and extreme levels of insulin
resistance like acanthosis nigricans syndrome, hyperandrogenism, the Rabson-
Mendenhall syndrome, lipodystrophy, and leprechaunism were discovered [12, 13].
To defend the idea by Himsworth that some cases of diabetes were not secondary to
absolute insulin deficiency, it was imperative to prove the truth that insulin circu-
lating in the blood was present in the insensitive form in those patients as classified
by Himsworth. This was put to rest with the publication by Yalow and Berson in 1960
of an immunoassay research of endogenous blood insulin in humans. During this
novel innovative work, Berson and Yalow delineated an excellent immunological
technique for measuring the amount of insulin that integrated the degree of
specificity with sensitivity required to take the measurement of even the smallest
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concentrations of insulin contained in the body circulation. Utilizing this novel tech-
nique to categorize immunoreactive insulin amounts present in plasma in normal
people to those particular patients having maturity-onset type diabetes, it was con-
ceived that the amounts of insulin were on the average elevated in the patients with
diabetes. Putting stress on the rationale of these particular outcomes, both of them
summarized that the tissues of a person with maturity-onset diabetes do not have a
good response to the level of insulin; on the contrary, the tissues of a nondiabetic
person respond very well to his level of insulin. In the words or terminology of
Himsworth, patients with this character in diabetes can be considered as “insulin
insensitive.” In spite of the fact these results of the novel publication by Yalow and
Berson were afterwards authenticated by various research groups, it became evident
that the interconnection between insulin concentrations and plasma glucose in
patients having type 2 diabetes was not such a simple one. To be precise, in a person
with comparatively slight increments of fasting plasma glucose concentration, the
responses of plasma insulin to oral glucose were equivalent or prominently higher
than the normal but with elevated proportions of glucose intolerance and with the
appearance of noteworthy hyperglycemia during fasting [14–17]. It was obligatory to
evolve an exploratory perspective that would quantify in an unequivocal way the
capability of an individual person to get rid of fixed glucose load under the influence
of identical insulin stimuli during steady-state conditions [18].
2. Risk factors for insulin resistance
A number of risk factors are found for insulin resistance, together with being
overweight or obese or pursuing a sedentary lifestyle [19]. Numerous genetic con-
stituents can elevate the chances for the same, and there are some particular med-
ical circumstances correlated with insulin resistance [19].
The National Institute of Diabetes and Digestive and Kidney Diseases has spec-
ified several hazard factors:
1.Age of 45 or more.
2.Native Alaskan, Asian American, American Indian, African American, Native
Hawaiian, or Latino/Hispanic ethnicity.
3.Having abnormal health states such as increased systolic/diastolic pressure and
increased levels of cholesterol.
4.Having gestational diabetes history.
5.Having a history stroke or heart disease [19].
6.In addition, somemedications and other health conditions can raise the risk [19].
2.1 Types of people more likely to develop insulin resistance
Individualswhohavehereditary factors or lifestyle-related factors are bound to have
in their later life insulin resistance or prediabetes [20]. Hazard factors incorporate:
• Overweight or obesity.
• Age 45 or more.
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• Having a parent, sibling, or sister with diabetes.
• African American, Alaskan Native, American Indian, Asian American,
Hispanic/Latino, Native Hawaiian, or Pacific Islander American ethnicity.
• Physical idleness.
• Health conditions, for example, hypertension and high cholesterol levels.
• A history of gestational diabetes.
• A history of coronary illness or stroke.
• Polycystic ovary disorder, also known as PCOS.
• Individuals who have metabolic disorder—hypertension, irregular cholesterol
levels, and enormous waist size—are bound to have prediabetes.
• Hormonal imbalances, for example, Cushing’s disorder and acromegaly.
• Sleep issues, particularly rest apnea.
In spite of the fact that you cannot change hazard factors, for example, family
ancestry, age, or ethnicity, you can change lifestyle factors such as eating, physical
activity, and weight. These ways of life changes can bring down your odds of
creating insulin resistance or prediabetes [21].
There are a number of other hazard factors that are firmly connected to insulin
resistance; however, these factors are yet to give clear answers about how much
these variables might be a reason for the same.
The variables include:
• Abundance of fat
• Having hypertension or hypercholesterolemia
• Having a nearby relative with type 2 diabetes
• History of gestational diabetes
• Having potential to develop type 2 diabetes
2.2 Diet
The food that we take are regularly seen as a conspicuous reason for diabetes and
frequently supposed as a reason.
Many studies have shown that our diet can have an effect in type 2 diabetes;
however, it is one factor among numerous others, and speculations ought not be
drawn without the thought of other contributing variables.
2.3 Contributions of genetics
Research has revealed various factors, which are related with an elevated danger
of diabetes. There are various elements which can impact our plasma glucose, as
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well as taking into consideration where we disperse fat in our body and how
efficiently our muscles allow glucose to enter from the blood.
It is a well-known fact that genes help control and regulate every metabolic
activity in the body, and mutations, in genes, which have influence in the digestion
and absorption process can cause problem with controlling blood glucose level. To
date scientists have distinguished more than 60 genes related with type 2 diabetes
mellitus (T2DM).
2.4 Medication
Corticosteroids treat mainly inflammatory disorders, as rheumatoid joint
inflammation, lupus, and hypersensitivities. Normal steroids incorporate hydrocor-
tisone and prednisone. Be that as it may, steroid creams (for a rash) or inhalers (for
asthma) aren’t an issue.
Medications that treat nervousness, attention deficit hyperactivity disorder
(ADHD), sorrow, and other emotional well-being issues can incorporate clozapine,
olanzapine, risperidone, and quetiapine:
• Contraception pills
• Medications that treat hypertension, for example, beta-blockers and thiazide
diuretics
• Statins to bring down cholesterol
• Adrenaline for serious hypersensitive responses
• High doses of asthma medications or medications that you infuse for asthma
treatment
• Isotretinoin for skin breakout
• Tacrolimus, which you get after an organ transplant
• A few meds that treat human immunodeficiency virus (HIV) and hepatitis
• Pseudoephedrine, a decongestant in some cold and influenza prescriptions
• Niacin or vitamin B3
Alongside these hazard factors, different things that may add to insulin
resistance incorporate:
• Antihypertensive agents such as β-blockers, diuretics, oral contraceptives,
corticosteroids, nicotinic acid, and antipsychotic agents are said to increase
insulin resistance [22, 23]; in addition, many anti-retroviral protease inhibitors
utilized to treat human immunodeficiency virus infection also cause insulin
resistance. The mechanisms of actions vary: β-blockers impede the secretion of
insulin from the pancreas by blocking the β-adrenoceptors, depletion of the
blood levels of potassium is the main action of thiazide diuretics, counter-
regulatory hormonal activity is the main action of oral contraceptives and
corticosteroids, and loss of peripheral subcutaneous fat with partial
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lipodystrophy (with resultant accumulation of truncal adipose tissue) is the
main action of HIV-1 protease inhibitors. All these ultimately lead to insulin
resistance [24].
2.5 Lifestyle factors
Many hormones can instigate insulin resistance, prominent among them being
human placental lactogen, growth hormone, and cortisol [25]. Counteraction of
insulin is done by cortisol and can cause elevated hepatic gluconeogenesis, decreas-
ing peripheral use of glucose and elevating insulin resistance [26]. Cortisol does this
by diminishing the translocation of glucose transporters (especially GLUT4) to the
respective cell membrane [27, 28]. This is based on the noteworthy augmentation in
the sensitivity of insulin in humans after doing bariatric surgery and surgical
removal of the duodenum in rats [29]; it has been speculated that some substance is
manufactured in the mucosa of duodenum, which gives a signal to the body cells to
become insulin resistant. With removal of the producing tissue, cessation of the
signal occurs, and reverting back of the body cells to normal insulin sensitivity is
seen. No such particular substance has been discovered as yet, and the certainty of
such a substance remains speculative. Leptin is a hormone derived from the adipo-
cytes and ob gene [30] whose role is the regulation of hunger by forewarning the
body when it is full [31]. Researches have depicted that dearth of leptin leads to
severe obesity and is intensely associated with insulin resistance [32].
3. Pathogenesis
Four major metabolic abnormalities characterize type 2 diabetes mellitus:
impaired insulin action, obesity, increased endogenous glucose output, and insulin
secretory dysfunction [33–35]. In spite of the fact that there is considerable authen-
tication that three of these idiosyncrasies exist in most people before the com-
mencement of diabetes, the concatenation with which they evolve and their
corresponding contributions to the advancement from normal glucose tolerance
(NGT) to impaired glucose tolerance (IGT), and ultimately to type 2 diabetes
[36–38], cannot be confirmed for sure even though some detailed longitudinal
studies have provided some information [39–44]. Contemporaneous comprehen-
sion of the pathogenesis of type 2 diabetes is established on a wide-reaching number
of cross-sectional [45–57] and prospective [58–72] studies. The evolution (and sub-
sequent progress) of type 2 diabetes mellitus is delineated by a gradual degeneration
of glucose tolerance over several years [33–38]. Prospective and cross-sectional data
demonstrate that defects in insulin secretion, body weight gain, insulin action, and
an elevation in endogenous glucose output are cardinal in this decline [45–56]. The
pathogenetic history of diabetes—the corporeal chain of events with which these
metabolic aberrations evolve in relation to one another throughout the various
stages of the illness—remains unrevealed. Many authors have suggested that a
flaw in insulin activity is the principal aberration in the premature stages of the
evolution of type 2 diabetes and that secretory dysfunction of insulin takes place
only at a later stage.
3.1 Molecular mechanism of insulin resistance in the muscle
Cellular contents of lipids inside myocytes (of muscles) are referred to as
intramyocellular lipid (IMCL) and basically reflect intramyocellular triglyceride
content. Although IMCL emphatically relates with muscle insulin resistance in
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inactive people, triglycerides themselves have been disassociated from insulin
resistance, recommending that other lipids (e.g., diacylglycerols, ceramides, and so
on) intervene insulin resistance [73]. Various investigations have depicted the
interrelationship insulin resistance in muscles and between diacylglycerol (DAG)
content. Insulin-animated tyrosine phosphorylation of insulin receptor substrate 1
(IRS-1) and IRS-1-related phospho-inositide 3-kinase (PI3K) actuation were
intensely debilitated in skeletal muscle of lipid-injected people [74] and rodents
[75, 76]. In rodents, lipids and high-fat intake bring about transient increments in
muscle DAG content [75], bringing about continued appearance of protein kinase
C-theta (PKCθ) that constrained phosphorylation of IRS-1 by insulin receptor
substrate 1 (IRTK). Lipid mixtures in normal human volunteers correspondingly
elevated skeletal muscle DAG [77, 78] and caused muscle insulin resistance. The
improvement of muscle insulin resistance can prompt metabolic ailment. This has
been seen in hereditary mouse models of particular muscle insulin resistance [79],
which are inclined to hepatic steatosis [75] and increased adiposity [77]. In young,
lean, and people with skeletal muscle insulin resistance, ingested glucose is not
taken up by muscle and gets occupied to the liver, where it becomes substrate for
liver once more by lipogenesis, increasing liver triglyceride; furthermore, plasma
triglyceride increase results in decreasing plasma high-density lipoprotein (HDL)
levels [80]. Nonalcoholic fatty liver disease (NAFLD) is unequivocally connected
with hepatic insulin resistance. In patients with lipodystrophy, ectopic lipid accu-
mulation in the liver and skeletal muscle was related with extreme hepatic and
muscle insulin resistance [81]. Leptin treatment diminished the consumption of
calorie, settled hepatic steatosis, and improved insulin activity [82]. Lipodystrophic
mice have a comparable phenotype, and fat transplantation protected these mice
by permitting redistribution of lipids from ectopic destinations to transplanted
fat tissue and standardization of insulin activity [83]. Mice overexpressing
lipoprotein lipase in the liver cause hepatic steatosis and liver-explicit insulin
resistance [84]. In rodents and mice, high-fat eating regimens lead to hepatic
steatosis and hepatic insulin resistance. In this way, these considerations show that
ectopic lipid in the liver is explicitly related with hepatic insulin resistance.
Magkos et al. showed that hepatic DAG content (not hepatic ceramide content) was
the best indicator of hepatic insulin resistance in obese people [85]. There are a few
conditions wherein hepatic steatosis shows up disassociated from hepatic insulin
resistance. A typical single-nucleotide polymorphism (rs738409, I48M) in the lipid
bead protein-like phospholipase domain-containing protein 3 [patatin-like phos-
pholipase domain-containing A3 gene (PNPLA3), likewise called adiponutrin
(ADPN)] has been related with expanded hepatic steatosis, but not insulin resis-
tance [86–88]. Along these lines, occasions of obvious disassociation of hepatic
steatosis and hepatic insulin opposition might be clarified by a superior compre-
hension of the subcellular conveyance of DAG [89]. Ceramides are additionally
bioactive lipid particles that are embroiled in the advancement of insulin resistance.
Increments in hepatic and muscle ceramide content have been related with insulin
resistance in rodents, and inhibitors of ceramide blend can forestall insulin resis-
tance [90, 91]. In any case, a disassociation between ceramide substance and tissue
insulin resistance has been revealed in numerous investigations [85, 92, 93], and the
fundamental component connecting ceramides to insulin resistance has not been
completely finalized. As of late, some investigations analyzed how a particular
ceramide species, C16:0, resists mitochondrial oxidation, permitting triglyceride to
accumulate and cause insulin resistance [94, 95]. Despite the fact it has not been
concluded, it is conceivable that the equal relationship between C16:0 ceramide and
mitochondrial oxidation could additionally cause increments DAG and impede
insulin action.
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3.2 Insulin resistance in the adipose tissue
Some of the actions of insulin on adipose tissue are (1) stimulation of uptake of
glucose and biosynthesis of triglyceride and (2) suppression of triglyceride
hydrolysis-cum release of free fatty acids (FFA) and glycerol into the blood [96, 97].
It has been seen that adipose tissue insulin resistance (Adipo-IR), which means
diminished suppression of lipolysis when high insulin levels are present, is interlinked
with glucose intolerance, and increased plasma FFA amounts have also shown to
diminish insulin signaling in muscles, endorse gluconeogenesis in the liver, and
diminish glucose-activated insulin response [97–103]. In spite of the fact that the
natural history and role of β-cell abnormality (or impairment) and insulin resistance
in muscle are firmly established in the evolution of T2DM, the influence of Adipo-IR
in the progression from normal glucose tolerance (NGT) to type 2 diabetes mellitus
(T2DM) is still not clear. It is possible to quantitate palmitate turnover by the utiliza-
tion of tracers [104–106] which can also provide the release rate of glycerol [107, 108]
to furnish a lipolysis index. Tracer turnover (i.e., labeled palmitate or glycerol) or FFA
suppression during insulin infusion (euglycemic-hyperinsulinemic clamp) or oral
glucose tolerance test (OGTT) has led to the development of a number of indices of
Adipo-IR [109]. Gastaldelli et al. [104] confirmed that fasting Adipo-IR index can be
considered as a reliable index of insulin resistance in the fat cell when considered over
the entire spectrum from NGT to T2DM. There has been consistent demonstration of
weakened suppression of plasma FFA and also glycerol and 14C-palmitate turnover
with the stepped hyperinsulinemic clamp [106, 110, 111] (i.e., adipocyte insulin
resistance) in persons having T2DM. Therefore a decline in insulin secretion/insulin
resistance (disposition) index has been seen with progression from lean NGT to obese
NGT to IGT [112]. A decline in the secretion from β-cell of insulin is also interlinked
with an elevation in the fasting Adipo-IR. Therefore, it can be said that the fasting
adipocyte insulin resistance index (fasting FFA  fasting insulin) increases in a
forward-looking, innovative manner over the stretch of glucose tolerance, extending
from NGT to T2DM, and furnishes a reliable index of fat cell sensitivity to the actions
of insulin [113–115]. In contradiction, there is increment of adipocyte insulin resis-
tance index during OGTT (fromNGT to IGT) and decrease with advancement of IGT
to T2DM; this is due to gradual deficiency of the secretion of insulin in this group
having diabetes. In conclusion, the gradual decrease in β-cell function that progresses
from NGT is interlinked with a gradual elevation in fasting Adipo-IR and FFA [104].
Fat insulin resistance is the failure of insulin to activate fat glucose transport,
advance lipid take-up, and diminish lipolysis. While diminished fat glucose take-up
is exhibited in both in vivo and in vitro models, metabolic effect of hindered
insulin-intervened glucose take-up in fat tissue is not well explained. For instance,
the loss of fat GLUT4 in mice does not modify adiposity or, on the other hand, how
weight gain prompts insulin resistance in skeletal muscle and liver [116]. Glucose
transport into fat cells initiates starch reaction component restricting protein
(ChREBP), which may affect fat lipid digestion [117]. Adipocytes discharge explicit
unsaturated fats that are related with increased insulin affectability, as palmitoleate
[118, 119] or monomethyl chain unsaturated fats [120].
4. Methods for diagnosis
4.1 Fasting insulin levels
A fasting serum insulin amount of more than 25 mU/L or in other sense
174 pmol/L designates insulin resistance. The same amounts pertain to 3 hours after
taking the last meal [121].
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4.2 Glucose tolerance testing
While performing a glucose tolerance test (GTT), a patient who is fasting is
given a 75 g of glucose orally. Then plasma glucose levels are continuously moni-
tored (along with urine glucose) for a period of 2 hours.
The elucidation of the test is established on the guidelines of the World Health
Organization (WHO). After a period of 2 hours, a plasma glucose amount of less than
7.8 mmol/L (140 mg/dL) is regarded as normal, and a plasma glucose amount of
between 7.8 and 11.0 mmol/L (140 to 197 mg/dL) is regarded as impaired glucose
tolerance (IGT), and a plasma glucose amount of greater than or equal to 11.1 mmol/L
(200 mg/dL) is regarded as diabetes mellitus. Extension of the testing (for several
more hours) may reveal a hypoglycemic “dip” that is a result of an overshoot in
insulin production after the failure of the physiologic postprandial insulin response.
4.3 Using the hyperinsulinemic euglycemic clamp
“Hyperinsulinemic euglycemic clamp” is also known as the gold standard for
investigating and quantifying insulin resistance. It is so-called because it calculates the
level of glucose obligatory to reimburse for an elevated insulin level without giving
rise to hypoglycemia [122]. It is a kind of glucose clamping technique. The test is
seldom carried out in clinical settings but is utilized in medical research [123]. The
process takes around 2 hours. Insulin is infused through a peripheral vein. The rate is
of infusion is 10–120 mU per m2/minute. With the intention to recompense for the
infusion of insulin, 20% glucose is infused to sustain blood glucose levels between 5
and 5.5 mmol/L. The blood sugar levels every 5 to 10 minutes, to determine the rate of
infusion of glucose [123]. The determination of insulin sensitivity is made by the rate
of glucose infusion in the last 30 minutes of the test. If greater levels (7.5 mg/min or
greater) are required, the patient is considered as insulin sensitive. Low levels such as
4.0 mg/min or lower than that designates that the body is resistant to actions of
insulin. Levels between 4.0 and 7.5 mg/min are not conclusive and indicate “impaired
glucose tolerance,” which is a premature gesticulation of insulin resistance [123, 127].
This basic method may be modified significantly by the utilization of glucose tracers.
4.4 Modified insulin suppression test
Gerald Reaven developed the modified insulin suppression test at Stanford
University. The test corresponds well with the euglycemic clamp, with minute
operator-dependent error. Particularly, this test has been utilized in research corre-
lating to the metabolic syndrome [123]. A 25 μg of octreotide (Sandostatin) is given
to the patient in 5 mL of normal saline over a period of 3–5 minutes through
intravenous infusion (IV) as a primary bolus. Subsequently, the patient is continu-
ously infused with an IV infusion of somatostatin (0.27 μg/m2/min) to repress
internal glucose and insulin secretion. Next, 20% glucose and insulin are infused at
varying rates of 32 and 267 mg/m2/min. Plasma glucose is monitored at 0, 30, 60,
90 minutes, and lastly at 120 minutes and subsequently after each 10 minutes for
the final 30 minutes of the study. The averages of these final four values are utilized
to ascertain the steady-state plasma glucose level (SSPG). People having an SSPG
greater than 150 mg/dL are contemplated to have insulin resistance [45].
4.5 Homeostatic model assessment (HOMA)
By this method it is possible to quantify insulin resistance. Also, pancreatic beta-
cell function can be possibly elucidated:
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HOMA‐IR ¼
Glucose Insulin
22:5
(1)
and
HOMA‐β ¼
20 Insulin
Glucose 3:5%
(2)
where glucose is in mmol/L.
Also,
HOMA‐IR ¼
Glucose Insulin%
405
(3)
and
HOMA‐β ¼
360 Insulin%
Glucose 63
(4)
where glucose is in mg/dL.
Note: insulin is taken in μU/mL; both glucose and insulin are taken during
fasting; IR means insulin resistance; HOMA-β is the percentage of beta cell function
[124–128].
4.6 Quantitative insulin sensitivity check index (QUICKI) method for insulin
assessment
QUICKI is obtained utilizing the inverse of the addition of the logarithms of the
fasting insulin and fasting glucose:
1= log fasting insulin μU=mLð Þ þ log fasting glucose mg=dLð Þ½  (5)
The QUICKI method corresponds well with glucose clamp researches (r = 0.78)
and is very good for the measurement of insulin sensitivity (IS), which is derived by
utilizing the reciprocal quantity of insulin resistance (IR).
5. Conclusions
From the time insulin resistance was discovered, the cellular and molecular
mechanisms were the considerations for which drugs were tried for diabetes
mellitus. Considering the cellular mechanisms of insulin resistance which are
mostly concerned with plasma cell membrane glycoprotein-1 (PC-1), also termed as
ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), the mechanism is
really complex. The full understanding of the cellular mechanisms will permit the
development of novel targets for various treatment modalities. From the therapeu-
tic point of view, we need to have a clear knowledge about the cellular mechanism
of insulin resistance in order to treat and also to prevent the occurrence of diabetes
from prediabetic stage. From recent studies, it is evident that insulin resistance
can be stopped or reversed if the pathophysiology is clear. It is the necessity to
implement a huge global strategic plan for identifying and preventing/treatment of
insulin resistance in the prediabetic stage.
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